Toronto - Delayed Quote CAD

Medexus Pharmaceuticals Inc. (MDP.TO)

2.8400

0.0000

(0.00%)

At close: June 9 at 3:59:59 PM EDT

Should We Be Delighted With Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 11%?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Simply Wall St. last month

MEDXF
Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with the provincial government of Quebec for Trecondyv® (treosulfan for injection). The Public Prescription Drug Insurance Plan of the Régie de l'Assurance Maladie du Québec, or RAMQ, will now reimburse eligible claims made for Trecondyv®.*"This development is another important reimbursement milestone for Trecondyv® because we have n

Newsfile last month

MEDXF
Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 7, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update on the progress of the commercial launch of GRAFAPEX™ (treosulfan) for Injection in the United States and announce company management's participation in two upcoming investor conferences.Medexus has seen an encouraging market response to GRAFAPEX™ in the weeks since the February 24 commercial launch of the product. Several procedures

Newsfile 2 months ago

MEDXF
Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 14, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the licensor of Medexus's rights to Gleolan® in the United States, to terminate the license, supply, and distribution agreement between the parties and return responsibility for Gleolan® in the United States to NXDC as of a date no later than March 31, 2025. Under the terms of the termination ...

Newsfile 2 months ago

MEDXF
Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 24, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that GRAFAPEX™ (treosulfan) for Injection is now commercially available in the United States."We are pleased to report this positive development, which marks a strategically important step forward for our business and, importantly, will now benefit eligible patients across the United States," commented Ken d'Entremont, Medexus's Chief Executive O

Newsfile 3 months ago

MEDXF
Medexus Pharmaceuticals Third Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Medexus Pharmaceuticals ( TSE:MDP ) Third Quarter 2025 Results Key Financial Results Revenue: US$30.0m (up 19% from 3Q...

Simply Wall St. 3 months ago

MEDXF
Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States

Fiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 million, and Adjusted EBITDA* of $5.8 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 6, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's third fiscal quarter ended December 31, ...

Newsfile 4 months ago

MEDXF
Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario Health (Cancer Care Ontario) for Trecondyv® (treosulfan for injection). The Ontario Public Drug Programs will now reimburse eligible claims made for Trecondyv®, subject to satisfaction of any relevant conditions set out in the agreements.¹"This important de

Newsfile 4 months ago

MEDXF
Medexus Schedules Third Fiscal Quarter 2025 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 6, 2025 to discuss Medexus's results for its third fiscal quarter ended December 31, 2024. Medexus expects to file its financial statements and MD&A after markets close on February 5, 2025.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian ...

Newsfile 4 months ago

MEDXF
Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals Inc. (TSX: MDP) ("Medexus" or the "Company"), is pleased to announce the closing of its previously announced overnight marketed underwritten offering (the "Offering") of 7,500,000 common shares of the Company (the "Common Shares") at a public offering price of $4.00 per Common Share for aggregate gross proceeds to the Company of $30,000,000. The Offering was completed pursuant to an underwriting

Newsfile 4 months ago

MEDXF
Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares

The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO and CHICAGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX: MDP), is pleased to announce the pricing and terms of its previously announced overnight marketed underwritten offering (the “Offering”) of 7,500,000

GlobeNewswire 4 months ago

MEDXF
Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares

NOT FOR DISTRIBUTION TO UNITED STATES TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”). The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the Company and Raymond James Ltd. as le

GlobeNewswire 4 months ago

MEDXF
Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update

Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million within five years after commercial launchToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 22, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update regarding the successful completion of the regulatory review process for GRAFAPEX™ (treosulfan) for injection with the US Food and Drug Administration and, in addition,

Newsfile 4 months ago

MEDXF
Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 15, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with British Columbia's Provincial Health Services Authority (PHSA), a publicly funded health service provider in the Canadian province, for a new approved indication for Trecondyv® (treosulfan for injection) to be listed on the BC Cancer Benefit Drug List and funded through BC Cancer, a part of PHSA that provides a province-wide p

Newsfile 4 months ago

MEDXF
Despite the downward trend in earnings at Medexus Pharmaceuticals (TSE:MDP) the stock spikes 16%, bringing one-year gains to 48%

If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...

Simply Wall St. 5 months ago

MEDXF
Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement, Setting Regulatory Milestone Amounts and Payment Schedule

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - December 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a fourth amendment to its February 2021 exclusive license agreement with medac relating to commercialization of treosulfan in the United States.Among other things, the fourth amendment adjusts the unpaid regulatory milestone payments under the US treosulfan agreement. Upon an FDA approval of treosulfan, Medex

Newsfile 6 months ago

MEDXF
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 18, 2024) - Earlier in November 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) successfully completed a negotiation process with the pan-Canadian Pharmaceutical Alliance seeking to make Trecondyv® (treosulfan for injection) accessible to publicly funded drug programs and patients in Canada. The pCPA is an independent organization whose membership includes the provincial, territorial, and federal governments.Reaching this

Newsfile 6 months ago

MEDXF
Some May Be Optimistic About Medexus Pharmaceuticals' (TSE:MDP) Earnings

Investors were disappointed with the weak earnings posted by Medexus Pharmaceuticals Inc. ( TSE:MDP ). However, our...

Simply Wall St. 6 months ago

MEDXF
Should We Be Cautious About Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 7.0%?

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Simply Wall St. 6 months ago

MEDXF
Medexus Announces Strong Fiscal Q2 2025 Results

Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of $1.6 million, and Adjusted EBITDA* of $6.0 millionManagement to host conference call at 8:00 AM Eastern time on Friday, November 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, ...

Newsfile 6 months ago

MEDXF

Performance Overview

Return	MDP.TO	S&P/TSX Composite index (^GSPTSE)
YTD	-13.68%	+7.13%
1-Year	+59.55%	+19.85%
3-Year	+27.93%	+28.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Medexus Pharmaceuticals Inc. (MDP.TO)

Should We Be Delighted With Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 11%?

Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada

Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection

Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.

Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection

Medexus Pharmaceuticals Third Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States

Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada

Medexus Schedules Third Fiscal Quarter 2025 Conference Call

Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares

Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares

Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares

Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update

Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada

Despite the downward trend in earnings at Medexus Pharmaceuticals (TSE:MDP) the stock spikes 16%, bringing one-year gains to 48%

Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement, Setting Regulatory Milestone Amounts and Payment Schedule

Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada

Some May Be Optimistic About Medexus Pharmaceuticals' (TSE:MDP) Earnings

Should We Be Cautious About Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 7.0%?

Medexus Announces Strong Fiscal Q2 2025 Results

Performance Overview